Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Br J Haematol ; 152(2): 201-10, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21114483

RESUMEN

Modern intensive chemotherapy for childhood haematological malignancies has led to high cure rates, but has detrimental effects on the immune system. There is little knowledge concerning long-term recovery of the adaptive immune system. Here we studied the long-term reconstitution of the adaptive immune system in 31 children treated for haematological malignancies between July 2000 and October 2006. We performed detailed phenotypical and functional analyses of the various B and T cell subpopulations until 5 years after chemotherapy. We show that recovery of newly-developed transitional B cells and naive B and T cells occurred rapidly, within months, whereas recovery of the different memory B and T cell subpopulations was slower and incomplete, even after 5 years post-chemotherapy. The speed of B and T cell recovery was age-independent, despite a significant contribution of the thymus to T cell recovery. Plasmablast B cell levels remained above normal and immunoglobulin levels normalised within 1 week. Functional T cell responses were normal, even within the first year post-chemotherapy. This study shows that after intensive chemotherapy for haematological malignancies in children, numbers of several memory B and T cell subpopulations were decreased on the long term, while functional T cell responses were not compromised.


Asunto(s)
Inmunidad Adaptativa/efectos de los fármacos , Antineoplásicos/farmacología , Neoplasias Hematológicas/tratamiento farmacológico , Neoplasias Hematológicas/inmunología , Adolescente , Factores de Edad , Subgrupos de Linfocitos B/efectos de los fármacos , Subgrupos de Linfocitos B/inmunología , Proliferación Celular/efectos de los fármacos , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Inmunoglobulinas/sangre , Inmunofenotipificación , Activación de Linfocitos/efectos de los fármacos , Recuento de Linfocitos , Masculino , Subgrupos de Linfocitos T/efectos de los fármacos , Subgrupos de Linfocitos T/inmunología , Timo/efectos de los fármacos , Timo/inmunología
2.
Leuk Res ; 35(4): 484-91, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21051085

RESUMEN

Chemotherapy for childhood acute lymphoblastic leukemia may cause severe immune damage. The lymphocyte compartment of 140 patients during and after a new strongly reduced (standard risk (SR), n=43) and intensive chemotherapy regimen (medium risk (MR), n=97) was studied between 2006 and 2009. Transitional and naive B cells and IgG(+)/A(+), IgM(+) and IgM only memory B cells were significantly reduced during chemotherapy; significantly more in MR group. One year after treatment CD27(+)IgG(+)/A(+), IgM(+) and IgM only memory B cells had still not fully recovered, but this was not confined to the MR group. The T cell compartment was less but also significantly affected during chemotherapy and recovered to normal levels. In the MR group, NK cells had not fully recovered to normal levels 1 year after treatment. Thus, intensive chemotherapy regimens cause severe, mainly B cell memory damage that persists even 1 year after treatment.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Leucemia-Linfoma Linfoblástico de Células Precursoras/inmunología , Adolescente , Linfocitos B/efectos de los fármacos , Linfocitos B/inmunología , Niño , Preescolar , Femenino , Citometría de Flujo , Humanos , Memoria Inmunológica/efectos de los fármacos , Memoria Inmunológica/inmunología , Lactante , Células Asesinas Naturales/efectos de los fármacos , Células Asesinas Naturales/inmunología , Recuento de Linfocitos , Linfocitos/efectos de los fármacos , Linfocitos/inmunología , Masculino , Linfocitos T/efectos de los fármacos , Linfocitos T/inmunología , Factores de Tiempo , Resultado del Tratamiento , Miembro 7 de la Superfamilia de Receptores de Factores de Necrosis Tumoral/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA